Literature DB >> 15719966

Detection of IMRT delivery errors using a quantitative 2D dosimetric verification system.

Nathan L Childress1, Charles Bloch, R Allen White, Mohammad Salehpour, Isaac I Rosen.   

Abstract

We investigated the feasibility of detecting intensity modulated radiotherapy delivery errors automatically using a scalar evaluation of two-dimensional (2D) transverse dose measurement of the complete treatment delivery. Techniques using the gamma index and the normalized agreement test (NAT) index were used to parametrize the agreement between measured and computed dose distributions to seven different scalar metrics. Simulated verifications with delivery errors calculated using a commercially available treatment planning system for 9 prostate and 7 paranasal sinus cases were compared to 433 clinical verifications. The NAT index with 5% and 3 mm criteria that included cold areas outside the planning target volume detected the largest percent of delivery errors. Assuming a false positive rate of 5%, it was able to detect 88% of beam energy changes, 94% of a different patient's plan being delivered, 25% of plans with one beam's collimator rotated by 90 degrees, 81% of rotating one beam's gantry angle by 10 degrees, and 100% of omitting the delivery of one beam. However, no instances of changing one beam's monitor unit setting by 10% or shifting the isocenter by 5 mm were detected. Although the phantom shift could not be detected by the small change it made in the dose distribution, our autopositioning algorithm clearly identified the spatial anomaly. Using tighter 3 %/2 mm criteria or combining dose and distance disagreements in an either/or fashion resulted in poorer delivery error detection. The mean value of the 2D gamma index distribution was less sensitive to delivery errors than the other scalar metrics studied. Although we found that scalar metrics do not have sufficient delivery error detection rates to be used as the sole clinical analysis technique, manually examining 2D dose comparison images would result in a near 100% detection rate while performing an ion chamber measurement alone would only detect 54% of these errors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15719966     DOI: 10.1118/1.1829171

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  6 in total

1.  Modification of the gamma function for the recognition of over- and under-dose regions in three dimensions.

Authors:  Mohammad Mohammadi; Nima Rostampour; Thomas P Rutten
Journal:  J Med Phys       Date:  2012-10

2.  Clinical implementation and error sensitivity of a 3D quality assurance protocol for prostate and thoracic IMRT.

Authors:  Gueorgui Gueorguiev; Christopher Cotter; Julie Catherine Turcotte; Bruce Crawford; Gregory Sharp; Mufeed Mah'D
Journal:  J Appl Clin Med Phys       Date:  2015-09-08       Impact factor: 2.102

3.  A critical evaluation of the PTW 2D-ARRAY seven29 and OCTAVIUS II phantom for IMRT and VMAT verification.

Authors:  Mohammad Hussein; Elizabeth J Adams; Thomas J Jordan; Catharine H Clark; Andrew Nisbet
Journal:  J Appl Clin Med Phys       Date:  2013-11-04       Impact factor: 2.102

4.  Clinical Experience of Intensity Modulated Radiotherapy Pre-Treatment Quality Assurance for Carcinoma Head and Neck Patients with EPID and IMatriXX in Rural Center.

Authors:  More M; Jain V; Gurjar O P
Journal:  J Biomed Phys Eng       Date:  2020-12-01

5.  On the sensitivity of patient-specific IMRT QA to MLC positioning errors.

Authors:  Guanghua Yan; Chihray Liu; Thomas A Simon; Lee-Cheng Peng; Christopher Fox; Jonathan G Li
Journal:  J Appl Clin Med Phys       Date:  2009-02-05       Impact factor: 2.102

6.  Detector system dose verification comparisons for arc therapy: couch vs. gantry mount.

Authors:  Arjunan Manikandan; Biplab Sarkar; Maitreyee Nandy; Chandra Sekaran Sureka; Michael S Gossman; Nadendla Sujatha; Vivek Thirupathur Rajendran
Journal:  J Appl Clin Med Phys       Date:  2014-05-08       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.